US Velsipity Consumer Team Lead

• United States - Massachusetts - Cambridge
• United States - Pennsylvania - Collegeville
• United States - New York - New York City

We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place.

To fully realize Pfizer’s purpose – Breakthroughs that change patients’ lives – we have established a clear set of expectations regarding “what” we need to achieve for patients and “how” we will go about achieving those goals.

Pfizer offers competitive compensation and benefits programs designed to meet the diverse needs of our colleagues.

Velsipity is a priority brand within Specialty Care, approved in October 2023 for the treatment of adults with moderate to severe ulcerative colitis (UC). As a first‑line oral advanced therapy for patients who have not achieved adequate response to conventional treatments, Velsipity offers a differentiated solution in a competitive and rapidly evolving landscape.

Supported by a strong product profile, Pfizer’s leadership in GI, and a substantial unmet need in UC, Velsipity is positioned to become a key growth driver within the portfolio. A critical priority for 2026 will be accelerating patient activation and increasing awareness of Velsipity’s value proposition as a safe and effective oral treatment option.

Velsipity is a priority brand within Specialty Care, approved in October 2023 for the treatment of adults with moderate to severe ulcerative colitis (UC). As a first‑line oral advanced therapy for patients who have not achieved adequate response to conventional treatments, Velsipity offers a differentiated solution in a competitive and rapidly evolving landscape.

Supported by a strong product profile, Pfizer’s leadership in GI, and a substantial unmet need in UC, Velsipity is positioned to become a key growth driver within the portfolio. A critical priority for 2026 will be accelerating patient activation and increasing awareness of Velsipity’s value proposition as a safe and effective oral treatment option.

The US Velsipity Consumer Team Lead will define and drive the strategic vision for the Consumer organization during a pivotal year for the brand. This leader will oversee all branded and unbranded consumer marketing efforts, guide the development of a new branded creative campaign (launching Q2 2026), and champion integrated, insight‑driven activation across channels.

The ideal candidate brings deep US marketing experience, a track record of advancing brand imperatives, and demonstrated success in consumer marketing and team leadership (formal or informal). This role will also function as a leader on the Velsipity US Marketing team and will represent on key enterprise initiatives. This role will directly lead a team of 3 marketers.

This role reports to the Velsipity Marketing Team Lead and partners closely with cross‑functional colleagues and agency partners.

• Serve as the strategic lead for all branded and unbranded patient activation initiatives.
• Create, own and manage the consumer omnichannel strategy inclusive of Social, Digital, CRM, and Patient Ambassador for both Branded and Unbranded advertising and patient education.
• Lead development of new branded consumer campaign.
• Develop a deep understanding of the patient journey including needs, insights and the role of patient communications and identify the need to customize targeting based on geography.
• Shape annual operating plan and tactical planning process for Consumer, ensuring alignment to brand priorities and activation goals.
• Oversee segmentation, targeting, and application of consumer insights to drive more personalized engagement.

• Optimize paid media strategy by shifting to more efficient digital channels and testing innovative opportunities to break through.
• Responsible for fostering a productive agency relationship and managing all projects within allocated budget, as applicable.
• Partner with CMO organization on updates to the Velsipity digital ecosystem, including the DTC Go‑to‑Market pilot and migration of unbranded UC content to Pfizer for All.
• Monitor…